Century Therapeutics (IPSC) Equity Average (2022 - 2025)
Historic Equity Average for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $193.1 million.
- Century Therapeutics' Equity Average fell 755.02% to $193.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.1 million, marking a year-over-year decrease of 755.02%. This contributed to the annual value of $173.1 million for FY2024, which is 2900.09% down from last year.
- Century Therapeutics' Equity Average amounted to $193.1 million in Q3 2025, which was down 755.02% from $225.2 million recorded in Q2 2025.
- In the past 5 years, Century Therapeutics' Equity Average registered a high of $372.3 million during Q2 2022, and its lowest value of $178.5 million during Q4 2024.
- Over the past 4 years, Century Therapeutics' median Equity Average value was $217.0 million (recorded in 2024), while the average stood at $243.5 million.
- In the last 5 years, Century Therapeutics' Equity Average plummeted by 3746.77% in 2024 and then soared by 1258.79% in 2025.
- Century Therapeutics' Equity Average (Quarter) stood at $316.5 million in 2022, then crashed by 36.17% to $202.0 million in 2023, then dropped by 11.62% to $178.5 million in 2024, then grew by 8.18% to $193.1 million in 2025.
- Its last three reported values are $193.1 million in Q3 2025, $225.2 million for Q2 2025, and $200.9 million during Q1 2025.